Canine atopic dermatitis: Role of luteolin as new natural treatment

Vet Med Sci. 2020 Nov;6(4):926-932. doi: 10.1002/vms3.325. Epub 2020 Aug 2.

Abstract

Background: Luteolin has been demonstrated to possess numerous biological effects. However, the effect of luteolin on LPS (Lipopolysaccharides) stimulation in CPEK cells has not been investigated.

Hypothesis/objectives: An in vitro model of atopic canine dermatitis was used to identify the antioxidant effect of luteolin as a new treatment that is capable of improving the conditions of veterinary patients.

Methods: CPEK cells were treated with or without luteolin in the presence or absence of LPS. A cell viability assay was performed to test luteolin toxicity and the protective effect of luteolin after LPS stimulation. Additionally, enzyme-linked immunosorbent assay (ELISA) kits were used to detect the levels of IL-33, IL-1β, IL-6, and IL-8.

Results: Luteolin was capable to significantly decrease levels expression of IL-33, IL 1β, IL-6, and IL-8.

Conclusions and clinical importance: Luteolin could be a new pharmacological treatment for canine atopic dermatitis.

Keywords: Canine atopic dermatitis; Luteolin; in vitro model; inflammation.

MeSH terms

  • Animals
  • Antioxidants / pharmacology*
  • Dermatitis, Atopic / drug therapy
  • Dermatitis, Atopic / veterinary*
  • Dog Diseases / drug therapy*
  • Dogs
  • Luteolin / pharmacology*

Substances

  • Antioxidants
  • Luteolin